[The responses of leukemia cells to interleukin-2 in vitro].
We conducted a study on the utility and safety of rhIL-2 immunotherapy for leukemia. The responses of leukemic cells expressing interleukin-2 receptor (IL-2R) gene obtained from 7 leukemic cell lines, 6 cases of acute lymphoblastic leukemia (ALL) and 8 cases of acute myeloid leukemia (AML) were measured by 3H-thymidine incorproation. The results showed that the responses of these cells were heterogeneous. The cells expressing IL-2R alpha and IL-R beta mRNAs simultanesously from NKL-1,2 cases of ALL and 1 cases of AML(M5) responded to rhIL-2 proliferatively; the cells from 3 leukemic cell lines, 2 cases of ALL and 2 cases of AML were inhibited by rhIL-2; the leukemic cells from the remaining 3 leukemic cell lines and 7 cases of leukemia did not respond to rhIL-2. The study demonstrates that the responses of leukemic cells expressing IL-2 receptors to rhIL-2 are heterogeneous. The patterns of the responses are proliferative, being inhibited to rhIL-2, or irresponsive. So rhIL-2 immunotherapy is suitable for the patients whose leukemic cells were inhibited by or did not respond to rhIL-2 in vitro, but this immunotherapy is not suitable for the patients whose leukemic cells responded proliferatively to rhIL-2 in vitro.
Yang
Y
Y
Department of Internal Medicine, First Affiliated Hospital, Chengdu.
D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007948:Leukemia, Monocytic, Acute / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000378:metabolism
D007376:Interleukin-2; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins